The point–of–care diagnostics market is estimated to be about $11.3 billion in size and growing at an annual rate over 11%. Components include consumer self–testing, primary care (physician’s office) testing and hospital emergency room testing.
Test categories include:
- Blood glucose
- Blood gas/electrolytes
- Hematology
- Pregnancy/fertility
- Tumor markers
- Cardiology
- Coagulation
- Infectious Disease
- Drugs of Abuse
- Clinical Chemistry/Urinalysis
Addressing the needs of point–of–care diagnosis is a logical extension of Cantimer’s technical capabilities. The company has already demonstrated “proof of principle” in the application of its technology to the detection and measurement of single strand DNA, proteins (Antigen/Antibody complexes), viruses (Vaccinia), electrolytes such as sodium and potassium, pH and a broad array of other analytes including ethanol, urea and glucose.
If you are interested in exploiting Cantimer’s broad sensor development capabilities in the development of proprietary diagnostic tests, please contact:
Ray Stewart, Ph.D.
Chief Technology Officer
rstewart@cantimer.com
(650) 474-0500, x302